Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction

Betancourt, Blas Y; Marrero-Miragaya, María A; Jiménez-López, Giset; Valenzuela-Silva, Carmen; García-Iglesias, Elizeth; Hernández-Bernal, Francisco; Debesa-García, Francisco; González-López, Tania; Alvarez-Falcón, Leovaldo; López-Saura, Pedro A.
BMC Clin Pharmacol ; 5Nov. 2005. tab
Artículo en Inglés | CUMED | ID: cum-39998

Documentos relacionados

  1. Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.
  2. Exposure Sources Among Veterans With Elevated Blood Lead Levels, United States, 2015‒2021.
  3. Should nasogastric tube be used routinely in patients undergoing cardiac surgery? A narrative review.
  4. Trends in the Use of Recombinant Activated Factor VII and Prothrombin Complex Concentrate in Heart Transplant Patients in Virginia.
  5. Exploring the natural history of intrinsic capacity impairments: longitudinal patterns in the 10/66 study.
  6. Obstetric outcomes in women with vulvodynia or vaginismus.
  7. Increased risk of hypocalcemia with decreased kidney function in patients prescribed bisphosphonates based on real-world data from the MID-NET<sup>®</sup> in Japan: a new-user cohort study.
  8. Changes in Infective Endocarditis Admissions in Pennsylvania During the Opioid Epidemic.
  9. Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea.
  10. Acute occupational inhalation injuries-United States, 2011-2022.